Veena Fauble

1.2k total citations
25 papers, 295 citations indexed

About

Veena Fauble is a scholar working on Hematology, Genetics and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Veena Fauble has authored 25 papers receiving a total of 295 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Hematology, 12 papers in Genetics and 7 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Veena Fauble's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (11 papers), Chronic Myeloid Leukemia Treatments (8 papers) and Acute Myeloid Leukemia Research (7 papers). Veena Fauble is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (11 papers), Chronic Myeloid Leukemia Treatments (8 papers) and Acute Myeloid Leukemia Research (7 papers). Veena Fauble collaborates with scholars based in United States, Italy and Germany. Veena Fauble's co-authors include José F. Leis, James L. Slack, Pierre Noël, Nandita Khera, Joseph Mıkhael, Lisa Sproat, Vivek Roy, Jon C. Tilburt, Timothy J. Beebe and Shahrukh K. Hashmi and has published in prestigious journals such as Blood, Bone Marrow Transplantation and Biology of Blood and Marrow Transplantation.

In The Last Decade

Veena Fauble

24 papers receiving 293 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Veena Fauble United States	9	168	112	77	77	61	25	295
Lisa Sproat United States	9	155 0.9×	42 0.4×	95 1.2×	77 1.0×	67 1.1×	18	340
Tanya L. Pedersen United States	8	479 2.9×	77 0.7×	283 3.7×	23 0.3×	64 1.0×	11	610
Tapan Saikia India	10	176 1.0×	126 1.1×	75 1.0×	30 0.4×	17 0.3×	32	311
Julia Foster United States	9	155 0.9×	55 0.5×	212 2.8×	12 0.2×	140 2.3×	17	360
Anthony Oyekunle Nigeria	11	192 1.1×	112 1.0×	54 0.7×	11 0.1×	11 0.2×	33	295
Nina Rosa Neuendorff Germany	10	128 0.8×	40 0.4×	64 0.8×	16 0.2×	11 0.2×	37	296
Jingbo Yu United States	12	260 1.5×	236 2.1×	59 0.8×	11 0.1×	39 0.6×	52	423
G Kardos Hungary	9	226 1.3×	46 0.4×	144 1.9×	8 0.1×	97 1.6×	28	391
Vivian Paintsil Ghana	11	72 0.4×	91 0.8×	102 1.3×	25 0.3×	215 3.5×	37	427
Birgith Engelst Grove Denmark	6	183 1.1×	35 0.3×	38 0.5×	18 0.2×	18 0.3×	12	299

Countries citing papers authored by Veena Fauble

Since Specialization

Citations

This map shows the geographic impact of Veena Fauble's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Veena Fauble with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Veena Fauble more than expected).

Fields of papers citing papers by Veena Fauble

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Veena Fauble. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Veena Fauble. The network helps show where Veena Fauble may publish in the future.

Co-authorship network of co-authors of Veena Fauble

This figure shows the co-authorship network connecting the top 25 collaborators of Veena Fauble. A scholar is included among the top collaborators of Veena Fauble based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Veena Fauble. Veena Fauble is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kim, Sunny, Dara James, Lakshmi Nair, et al.. (2025). Testing the feasibility of a digital storytelling intervention combined with heart rate variability biofeedback in hematopoietic cell transplant patients. Journal of Clinical and Translational Science. 9(1). e35–e35. 1 indexed citations

Jain, Tania, Katie L. Kunze, Luke Mountjoy, et al.. (2020). Early post-transplantation factors predict survival outcomes in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis. Blood Cancer Journal. 10(3). 36–36. 13 indexed citations

Palmer, Jeanne, Heidi Kosiorek, Christine Wolschke, et al.. (2019). Assessment of Quality of Life following Allogeneic Stem Cell Transplant for Myelofibrosis. Biology of Blood and Marrow Transplantation. 25(11). 2267–2273. 5 indexed citations

Jain, Tania, Katie L. Kunze, M’hamed Temkit, et al.. (2018). Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis. Bone Marrow Transplantation. 54(2). 204–211. 28 indexed citations

Hilal, Talal, Veena Fauble, Rhett P. Ketterling, & Katalin Kelemen. (2017). Myeloid neoplasm with eosinophilia associated with isolated extramedullary FIP1L1/PDGFRA rearrangement. Cancer Genetics. 220. 13–18. 6 indexed citations

Schriber, Jeffrey, et al.. (2017). No Differences in Stem Cell Transplantation Utilization Rates (STUR) by Ethnicity after Referral to a Transplant Center for Multiple Myeloma (MM): Implications for Improving Stur Rates in Minorities. Biology of Blood and Marrow Transplantation. 23(3). S270–S271. 1 indexed citations

Tamari, Roni, Tariq I. Mughal, Damiano Rondelli, et al.. (2015). Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era?. Bone Marrow Transplantation. 50(5). 628–636. 8 indexed citations

Slack, James L., et al.. (2015). Folinic Acid Rescue after Methotrexate Graft Versus Host Disease Prophylaxis to Reduce Mucositis and Improve the Probability of Day +11 Methotrexate Administration - Role of the Hematopoietic Cell Transplant Pharmacist in Development of Program Guidelines. Biology of Blood and Marrow Transplantation. 21(2). S121–S121. 1 indexed citations

Khera, Nandita, Yu‐Hui Chang, James L. Slack, et al.. (2014). Impact of race and ethnicity on outcomes and health care utilization after allogeneic hematopoietic cell transplantation. Leukemia & lymphoma. 56(4). 987–992. 16 indexed citations

10.

Khera, Nandita, Yu‐Hui Chang, Shahrukh K. Hashmi, et al.. (2014). Financial Burden in Recipients of Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation. 20(9). 1375–1381. 106 indexed citations

11.

Chang, Yu‐Hui, Pierre Noël, José F. Leis, et al.. (2014). Factors Affecting the Incidence of Severe (Stage 2-4) Gastrointestinal (GI) Graft-Versus-Host Disease (GVHD) in Adult Patients (pts) Undergoing Allogeneic Hematopoietic Transplant (Allo-HCT) for Hematologic Malignancy. Biology of Blood and Marrow Transplantation. 20(2). S262–S262. 2 indexed citations

12.

Slack, James L., Amylou C. Dueck, Veena Fauble, et al.. (2013). Reduced Toxicity Conditioning and Allogeneic Stem Cell Transplantation in Adults Using Fludarabine, Carmustine, Melphalan, and Antithymocyte Globulin: Outcomes Depend on Disease Risk Index but Not Age, Comorbidity Score, Donor Type, or Human Leukocyte Antigen Mismatch. Biology of Blood and Marrow Transplantation. 19(8). 1167–1174. 13 indexed citations

13.

Chaudhuri, Leena, James M. Bogenberger, Lisa Sproat, et al.. (2013). The Wee1 Inhibitor MK1775 In Combination With Cytarabine (AraC) Has Potent Activity In AML By Completely Abrogating DNA Damage and Cell Cycle Checkpoint Repair Capacity Via The Mrn/NBS1 Complex. Blood. 122(21). 3831–3831. 1 indexed citations

14.

Beebe, Kristen, Yu‐Hui Chang, Jane M. Palmer, et al.. (2013). Impact Of Vitamin D Level Pre and Post Allogeneic Hematopoietic Stem Cell Transplant. Blood. 122(21). 4616–4616. 4 indexed citations

15.

Palmer, Jane M., Roberta H. Adams, Veena Fauble, et al.. (2013). Clofarabine Salvage in Refractory Acute Myeloid Leukemia Before Allogeneic Stem Cell Tranplant. Biology of Blood and Marrow Transplantation. 19(2). S229–S230.

16.

Tibes, Raoul, Steven M. Kornblau, William E. Pierceall, et al.. (2013). BH3 Profiling As Predictor Of 5-Azacytidine and Decitabine Clinical Responses. Blood. 122(21). 603–603. 1 indexed citations

17.

Khera, Nandita, Yu‐Hui Chang, Shahrukh K. Hashmi, et al.. (2013). Financial Burden In Recipients Of Allogeneic Hematopoietic Cell Transplantation. Blood. 122(21). 721–721. 32 indexed citations

18.

Klein, Jared, James L. Slack, Veena Fauble, et al.. (2013). Short Course Infliximab and Extracorporeal Photopheresis As Therapy For Steroid-Refractory Acute Gvhd In Matched Related and Unrelated Allogeneic Hematopoietic Cell Transplant (HCT). Blood. 122(21). 4590–4590. 1 indexed citations

19.

Slack, James L., José F. Leis, Roberta H. Adams, et al.. (2012). Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase. Leukemia Research. 36(9). 1147–1151. 33 indexed citations

20.

Fauble, Veena, José F. Leis, & Ruben A. Mesa. (2012). Allogeneic stem cell transplant for myelofibrosis patients over age 60: likely impact of the JAK2 inhibitors. PubMed. 1(S1). S2–S7. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact